Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hibiscus 2 phase 3 study of etavopivat in sickle cell disease
2023-509175-16-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Etavopivat 200 mg with Placebo (2 arms). Primary endpoint: Number of adjudicated vaso-occlusive crisis (VOC) events with a medical contact. Planned start Mar 2025; status: authorised.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2023-509175-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509175-16-00.